Overview

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Status:
Not yet recruiting

Trial end date:
2023-12-15

Target enrollment:

Participant gender:

Summary

This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

Phase:

Phase 2

Details

Lead Sponsor:

River 3 Renal Corp.

Collaborator:

IQVIA Biotech